| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 08/05/2024 | 13:20 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:IMUX | Immunic Inc |
| 08/05/2024 | 12:45 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:IMUX | Immunic Inc |
| 08/05/2024 | 12:30 | PR Newswire (US) | Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update | NASDAQ:IMUX | Immunic Inc |
| 06/05/2024 | 12:30 | PR Newswire (US) | Immunic to Participate in Investor and Scientific Conferences in May | NASDAQ:IMUX | Immunic Inc |
| 01/05/2024 | 12:30 | PR Newswire (US) | Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update | NASDAQ:IMUX | Immunic Inc |
| 30/04/2024 | 12:30 | PR Newswire (US) | Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation | NASDAQ:IMUX | Immunic Inc |
| 04/04/2024 | 12:30 | PR Newswire (US) | Immunic to Host MS R&D Day and Participate in Investor Conferences in April | NASDAQ:IMUX | Immunic Inc |
| 20/03/2024 | 11:30 | PR Newswire (US) | Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States | NASDAQ:IMUX | Immunic Inc |
| 07/03/2024 | 12:30 | PR Newswire (US) | Immunic to Participate in Investor and Scientific Conferences in March | NASDAQ:IMUX | Immunic Inc |
| 07/03/2024 | 03:52 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:IMUX | Immunic Inc |
| 29/02/2024 | 12:30 | PR Newswire (US) | Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024 | NASDAQ:IMUX | Immunic Inc |
| 22/02/2024 | 12:38 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:IMUX | Immunic Inc |
| 22/02/2024 | 12:30 | PR Newswire (US) | Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update | NASDAQ:IMUX | Immunic Inc |
| 15/02/2024 | 12:30 | PR Newswire (US) | Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update | NASDAQ:IMUX | Immunic Inc |
| 14/02/2024 | 22:05 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:IMUX | Immunic Inc |
| 13/02/2024 | 22:36 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of 1933 | NASDAQ:IMUX | Immunic Inc |
| 05/02/2024 | 14:30 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements | NASDAQ:IMUX | Immunic Inc |
| 01/02/2024 | 12:30 | PR Newswire (US) | Immunic to Participate in Investor and Scientific Conferences in February | NASDAQ:IMUX | Immunic Inc |
| 24/01/2024 | 23:05 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements | NASDAQ:IMUX | Immunic Inc |
| 19/01/2024 | 22:05 | Edgar (US Regulatory) | Form D - Notice of Exempt Offering of Securities | NASDAQ:IMUX | Immunic Inc |
| 16/01/2024 | 22:12 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:IMUX | Immunic Inc |
| 05/01/2024 | 12:35 | PR Newswire (US) | Immunic Highlights 2023 Accomplishments and Upcoming Milestones | NASDAQ:IMUX | Immunic Inc |
| 05/01/2024 | 12:30 | PR Newswire (US) | Immunic, Inc. Announces Private Placement of up to $240 Million | NASDAQ:IMUX | Immunic Inc |
| 21/11/2023 | 12:30 | PR Newswire (US) | Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dosing Regimens in Multiple Sclerosis | NASDAQ:IMUX | Immunic Inc |
| 14/11/2023 | 12:30 | PR Newswire (US) | Immunic, Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Update | NASDAQ:IMUX | Immunic Inc |
| 07/11/2023 | 12:30 | PR Newswire (US) | Immunic to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide Corporate Update | NASDAQ:IMUX | Immunic Inc |
| 02/11/2023 | 11:30 | PR Newswire (US) | Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts | NASDAQ:IMUX | Immunic Inc |
| 26/10/2023 | 12:30 | PR Newswire (US) | Immunic to Participate in Scientific and Industry Conferences in November | NASDAQ:IMUX | Immunic Inc |
| 16/10/2023 | 12:30 | PR Newswire (US) | Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023 | NASDAQ:IMUX | Immunic Inc |
| 15/10/2023 | 12:30 | PR Newswire (US) | Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023 | NASDAQ:IMUX | Immunic Inc |